

HEALTH CARE PROVIDER INFORMATION

INSTITUTION/PRACTICE	ADDRESS (STREET NAME, NO., CITY, POSTCODE, COUNTRY)
FIRST NAME	TELEPHONE NUMBER (COUNTRY CODE & NUMBER)
LAST NAME	E-MAIL ADDRESS (FOR REPORT ACCESS)

PATIENT INFORMATION

FIRST NAME	ADDRESS (STREET NAME, NO., CITY, POSTCODE, COUNTRY)
LAST NAME	TELEPHONE NUMBER (COUNTRY CODE & NUMBER)
DATE OF BIRTH (DD/MM/YYYY)	IDENTIFICATION NO. (IF APPLICABLE)
GENETIC SEX ☐ FEMALE ☐ MALE ☐ OTHER (SPECIFY KARYOTYPE IF KNOWN):	

Please complete the above two sections in English.

SAMPLE MATERIAL

Collection date: _____	☐ EDTA blood (2-5 mL)	☐ Other (specify): _____ (Prior approval is required, please contact us in advance for more information)
Time: _____	☐ DNA from _____ (≥ 250 ng; ≥ 100 ng/μL)	
	☐ Buccal swab	

TEST INFORMATION

The **PGx preventive panel** is a preemptive screening test designed to support safer, more personalised prescribing by identifying genetic variants that affect drug metabolism, transport, and pharmacodynamic response.

Please note, that the PGx preventive panel is not a diagnostic test.

For further information on gene content, please visit our website: www.medicover-genetics.com.
If you have additional questions or concerns, please contact us at info.genetics@medicover.com

PHYSICIAN'S CONFIRMATION

I confirm that informed consent has been obtained from the patient (or legal guardian) for this preventive pharmacogenomic test. The patient has received sufficient information about the test, had the opportunity to ask questions, and was given adequate time to make an informed decision. I am authorised to request this test and confirm that appropriate counselling has been provided.

Name of the ordering physician

FIRST NAME	LAST NAME
SIGNATURE OF THE ORDERING PHYSICIAN	DATE OF SIGNATURE

PATIENT DECLARATION OF CONSENT

Please read this declaration carefully.

By signing this form, I confirm that I:

- ☐ Have been informed about the purpose, scope, and limitations of this pharmacogenomic test.
- ☐ Consent to the collection and analysis of my sample for the purpose of pharmacogenomic testing.
- ☐ Consent to the collection and analysis of my sample for the purpose of pharmacogenomic testing.
- ☐ Consent to the processing of my personal and genetic data in accordance with EU's General Data Protection Regulation (GDPR), Germany's Genetic Diagnostics Act (GenDG – Gendiagnostikgesetz), and EU's In Vitro Diagnostic Medical Devices Regulation (IVDR).
- ☐ Understand that I may withdraw my consent at any time without giving a reason, and request deletion of my data.
- ☐ Understand that I will only be charged for costs incurred up to the point of withdrawal.
- ☐ Understand that I may choose not to receive the results (right not to know).
- ☐ Acknowledge that this test analyses only selected pharmacogenes and does not provide information about other diseases.
- ☐ Have had the opportunity to ask questions and receive clear answers.

Additional consents and information. By signing this form, I confirm that I:

- YES NO
- ☐ ☐ Consent to the storage of my sample and results beyond the statutory minimum period (10 years), and to the use of pseudonymised material for quality assurance or scientific purposes (no claim to long-term storage).
 - ☐ ☐ Allow the test order form or parts of it to be shared with collaborating laboratories if needed.
 - ☐ ☐ Consent to the pseudonymised use of surplus sample and/or data for scientific research.

In addition:

- ☐ consent to sharing a copy of my test results with the following physician or healthcare provider, in line with my explicit request and the internal procedures of _____ (legal entity name).

PHYSICIAN NAME
STREET

POSTCODE/CITY
COUNTRY

Completed by: ☐ Patient ☐ Parent/Legal Guardian

FIRST NAME
SIGNATURE OF PATIENT/LEGAL GUARDIAN

LAST NAME
DATE OF SIGNATURE

IMPORTANT DISCLAIMERS

The following disclaimers provide important background information about the PGx preventive panel. Patients (or legal guardians) are encouraged to read them before signing the consent form, and physicians or healthcare professionals should be familiar with them as part of the test ordering process.

Scope & Purpose

This pharmacogenomic test is designed for preemptive screening and preventive use. It provides insights into drug metabolism based on genetic variation. It is not a diagnostic test and must not be used to detect, confirm, or treat disease.

Medical Disclaimer

The results do not constitute medical advice. They do not replace a clinical evaluation. All findings must be interpreted by a qualified healthcare professional.

Regulatory Compliance

This test is conducted in accordance with the German Genetic Diagnostics Act (GenDG), In Vitro Diagnostic Medical Devices Regulation (IVDR), and General Data Protection Regulation (GDPR). It is performed in an ISO 15189-accredited laboratory.

Physician Consultation

Patients are strongly encouraged to consult their physician. In Germany, the test is classified as preventive (GenDG) and does not require mandatory specialist genetic counselling before results are released.

Limitations

This test analyses a selected set of clinically validated pharmacogenes. It does not cover all genetic variants or gene–drug interactions. Environmental, lifestyle, or comorbid factors are not assessed.

Data Protection & Usage

All data is processed in accordance with GDPR. Patients may request data deletion at any time.

Right Not to Know

As per GenDG, patients may opt not to receive their test results and may withdraw consent at any time.